Next Article in Journal
The Possibility of Decreasing 50-Hz Electric Field Exposure near 400-kV Power Lines with Arc Flash Personal Protective Equipment
Next Article in Special Issue
Non-Obese Diabetes and Its Associated Factors in an Underdeveloped Area of South China, Guangxi
Previous Article in Journal
Pesticide Residues on Three Cut Flower Species and Potential Exposure of Florists in Belgium
Previous Article in Special Issue
The Effects of Intensive Nutrition Education on Late Middle-Aged Adults with Type 2 Diabetes
Article Menu

Export Article

Open AccessReview
Int. J. Environ. Res. Public Health 2016, 13(10), 941; doi:10.3390/ijerph13100941

The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review

Faculty of Education and Health, University of Greenwich, Avery Hill Campus, London SE9 2UG, UK
Academic Editor: Paul B. Tchounwou
Received: 18 June 2016 / Revised: 3 September 2016 / Accepted: 20 September 2016 / Published: 23 September 2016
(This article belongs to the Collection Health Care and Diabetes)
View Full-Text   |   Download PDF [292 KB, uploaded 23 September 2016]

Abstract

Objective: This review examines the use of exenatide twice daily in managing changes in markers of cardiovascular risk in patients with type 2 diabetes. Background: Type 2 diabetes is a progressive metabolic disorder, which results from defects in insulin secretion and/or insulin action leading to chronic hyperglycaemia and associated cardiovascular complications. Despite the use of diet, exercise, oral antihyperglycaemic agents and insulin, the progressive nature of the condition means that the levels of the preventive and treatment measures would have to be increased and/or new therapies have to be developed in order to address the long term impact of type 2 diabetes. The advent of exenatide, a glucagon-like peptide-1 receptor agonist provides a useful basis for managing type 2 diabetes and related cardiovascular complications without the side effects of regular diabetes therapies. However, exenatide twice daily is often used in combination with other therapies, although the mechanism of exenatide in managing diabetes and and associated cardiovascular risks and complications remain complex and still evolving. Method: A range of databases including EBSCOhost online research database were used to access articles based on PICO (Population, Interventions, Comparative Interventions, Outcomes) framework and Boolean operators. Results: Eleven randomised controlled studies which met the inclusion criteria were selected for this review. Nine of the eleven studies showed significant decrease in body weight among participants in the exenatide group compared with placebo or control group while the other two studies did not report statistically significant differences in body weight. In adition, all the studies showed statistically significant decrease in glycated haemoglobin (HbA1c) in the exenatide group compared to controls except in one study. In the present review, the seven studies, which looked at the effect of exenatide twice daily on lipid profile, did not find any significant difference between the exenatide group and the control group except for High density lipoprotein-cholesterol in two of the studies. However, statistically significant decrease was observed between exenatide group and controls with respect to blood pressure (systolic and/or diastolic) in these studies. Discussion: It would appear that exenatide is more effective in reducing body weight in patients with type 2 diabetes when used in combination with metformin than when used alone or in combination with thiazolidinedione. The findings of this review would suggest that exenatide twice daily may be useful in managing cardiovascular risks and complications by reducing body weight, HbA1c and blood pressure. View Full-Text
Keywords: exenatide; type 2 diabetes; cardiovascular risk; glycated haemoglobin; glycaemic control; metformin exenatide; type 2 diabetes; cardiovascular risk; glycated haemoglobin; glycaemic control; metformin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ojo, O. The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review. Int. J. Environ. Res. Public Health 2016, 13, 941.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top